Pedruzzi Paola A G, Kowalski Luiz P, Nishimoto Ines N, Oliveira Benedito V, Tironi Fabio, Ramos Gyl H A
Department of Head and Neck Surgery, Erasto Gaertner Hospital, Curitiba, Brazil.
Arch Otolaryngol Head Neck Surg. 2008 Nov;134(11):1196-204. doi: 10.1001/archotol.134.11.1196.
To assess the prognostic significance of several factors in oropharyngeal squamous cell carcinoma treated with radiotherapy alone or in combination with chemotherapy.
Retrospective study.
Erasto Gaertner Hospital, Curitiba, Brazil, and A. C. Camargo Hospital, São Paulo, Brazil.
A total of 361 patients treated for squamous cell carcinoma from January 1, 1990, to December 31, 2001.
Radiotherapy alone or with chemotherapy.
Disease-free survival, overall survival, and treatment response.
Most tumors were located at the tonsil (46.8%) or base of the tongue (28.0%) and were at clinical stage III or IV (92.8%). Treatment response was associated with Zubrod scale score, weight loss, number of comorbidities, symptom-severity and Piccirillo stages, hemoglobin level, tumor site, macroscopic appearance of the tumor, and clinical stage. The 5-year overall survival rate was 17.6% and disease-free survival rate was 16.2%. The significant prognostic variables were age; Zubrod scale score; weight loss; comorbidities; Berg, Piccirillo, and symptom-severity staging; involvement of adjacent soft-tissue areas and bone; lymph node mobility; clinical stage; and radiotherapy doses. The multivariate analysis showed Zubrod scale score, symptom-severity staging system, Berg staging system, comorbidities, and radiotherapy dose as independent prognostic factors.
A combination of clinical factors, such as symptoms, patients' general status, weight loss, and comorbidities, leads to a relevant stage of clinical severity that can be associated with the TNM stage as predictors of survival in oropharyngeal carcinoma.
评估单纯放疗或放化疗联合治疗口咽鳞状细胞癌时,多种因素的预后意义。
回顾性研究。
巴西库里蒂巴的埃拉斯托·盖特纳医院以及巴西圣保罗的A.C.卡马戈医院。
1990年1月1日至2001年12月31日期间共361例接受鳞状细胞癌治疗的患者。
单纯放疗或联合化疗。
无病生存期、总生存期和治疗反应。
大多数肿瘤位于扁桃体(46.8%)或舌根(28.0%),临床分期为III期或IV期(92.8%)。治疗反应与Zubrod评分、体重减轻、合并症数量、症状严重程度和Piccirillo分期、血红蛋白水平、肿瘤部位、肿瘤大体外观及临床分期相关。5年总生存率为17.6%,无病生存率为16.2%。显著的预后变量包括年龄;Zubrod评分;体重减轻;合并症;Berg、Piccirillo和症状严重程度分期;相邻软组织区域和骨骼受累情况;淋巴结活动度;临床分期;以及放疗剂量。多因素分析显示Zubrod评分、症状严重程度分期系统、Berg分期系统、合并症和放疗剂量为独立的预后因素。
症状、患者一般状况、体重减轻和合并症等临床因素的综合作用导致了一个相关的临床严重程度阶段,该阶段可与TNM分期相关联,作为口咽癌生存的预测指标。